Chicago Cornea Consultants Ltd — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$54,000	7
2024	Research	$12,000	3
2023	Research	$356	1
2022	Research	$12,729	3
2021	Research	$2,000	1
2020	Research	$10,879	7
2019	Research	$36,849	21

Breakdown

Who paid Research payments · program years 2019–2025

RxSight Inc $66,000 10 payments
Alcon Research LLC $22,771 16 payments
Kala Pharmaceuticals, Inc. $22,457 10 payments
Oyster Point Pharma, Inc. $13,085 4 payments
Kowa Research Institute, Inc. $2,500 2 payments
Aerie Pharmaceuticals, Inc. $2,000 1 payment

Studies the money was for Research payments · program years 2019–2025

Pmcs-010 $66,000 10 payments
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease $22,457 10 payments
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study $17,560 12 payments
A Single-Arm Investigatorinitiated Study to Evaluate Theefficacy of Oc-01 (Varenicline Solution) Nasal Spray on Refractive Accuracy and Signs and Symptoms of Dry Eye Subjects Udnergoing Iol Implant Cataract Surgery $9,250 1 payment
Comparison between iLux and LipiFlow in the treatment of MGD 12 month study $5,211 4 payments
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $3,479 2 payments
K-321-201 $2,500 2 payments
A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs) $2,000 1 payment
A Phase 2 Multicenter Randomized Controlled Double-Masked Clinical Trial to Evaluate the Efficacy and Safety of Oc-01 (Varenicline) Nasal Spray in Subjects With Neurotrophic Keratopathy (The Olympia Study) $356 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.